Vancouver, Canada

Colin C Collins


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:

goldMedal1 out of 832,680 
Other
 patents

Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovator Behind Apoptotic Inhibitor Therapeutics: Colin C. Collins

Introduction: Colin C. Collins, a notable inventor based in Vancouver, CA, has significantly contributed to the field of cancer treatment with his innovative patent. Focusing on advanced therapeutic compositions, he has aimed to tackle some of the most challenging forms of cancer encountered in modern medicine.

Latest Patents: Colin C. Collins holds a patent titled “Dual targeting antisense oligonucleotides as apoptotic inhibitor therapeutic compositions and methods for their use in the treatment of cancer.” This groundbreaking invention offers compositions, methods, and uses for modulating inhibitor of apoptosis protein (IAP) activity for effective cancer treatment. The patented compositions include dual-targeting antisense oligonucleotides (dASO) specifically designed for administration to cancer cells characterized by elevated expression of proteins such as BIRC6, cIAP1, or survivin. His work specifically addresses various cancer types, including prostate cancer (particularly castration-resistant prostate cancer), childhood de novo acute myeloid leukemia, colorectal cancer, neuroblastoma, melanoma, and non-small cell lung cancer.

Career Highlights: With a singular patent to his name, Colin C. Collins has demonstrated a profound understanding of cancer biology and the intricacies of therapeutic development. His innovative approach to targeting specific cancer pathways illustrates not only technical skill but also a commitment to advancing public health through effective treatment options.

Collaborations: Throughout his career, Collins has had the opportunity to collaborate with distinguished colleagues, including Yuzhuo Wang and Hui Xue. These partnerships highlight the collaborative nature of scientific research and the importance of teamwork in addressing complex health challenges such as cancer.

Conclusion: In conclusion, Colin C. Collins stands out as a dedicated inventor working towards innovative solutions in cancer therapy. His patent on dual-targeting antisense oligonucleotides reflects his commitment to improving treatment modalities for various forms of cancer. With ongoing collaborations and a focus on therapeutic development, Collins continues to be an influential figure in the field of cancer research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…